NO994630L - Metoder for behandling av vaskulaere sykdommer - Google Patents

Metoder for behandling av vaskulaere sykdommer

Info

Publication number
NO994630L
NO994630L NO994630A NO994630A NO994630L NO 994630 L NO994630 L NO 994630L NO 994630 A NO994630 A NO 994630A NO 994630 A NO994630 A NO 994630A NO 994630 L NO994630 L NO 994630L
Authority
NO
Norway
Prior art keywords
treatment
methods
vascular diseases
medicament
dose
Prior art date
Application number
NO994630A
Other languages
English (en)
Norwegian (no)
Other versions
NO994630D0 (no
Inventor
Brian William Grinnell
Daniel C Howey
Charles V Jackson
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO994630D0 publication Critical patent/NO994630D0/no
Publication of NO994630L publication Critical patent/NO994630L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
NO994630A 1997-03-24 1999-09-23 Metoder for behandling av vaskulaere sykdommer NO994630L (no)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US4253397P 1997-03-24 1997-03-24
US6254997P 1997-10-20 1997-10-20
US6476597P 1997-11-07 1997-11-07
PCT/US1998/005732 WO1998042358A1 (en) 1997-03-24 1998-03-24 Methods for treating vascular disorders

Publications (2)

Publication Number Publication Date
NO994630D0 NO994630D0 (no) 1999-09-23
NO994630L true NO994630L (no) 1999-09-23

Family

ID=27366150

Family Applications (1)

Application Number Title Priority Date Filing Date
NO994630A NO994630L (no) 1997-03-24 1999-09-23 Metoder for behandling av vaskulaere sykdommer

Country Status (19)

Country Link
EP (1) EP0872245B1 (ko)
JP (1) JP4680329B2 (ko)
KR (1) KR20010005626A (ko)
CN (1) CN1168492C (ko)
AT (1) ATE319472T1 (ko)
AU (1) AU733756B2 (ko)
BR (1) BR9808063A (ko)
CA (1) CA2284279A1 (ko)
DE (1) DE69833727T2 (ko)
EA (1) EA199900862A1 (ko)
ES (1) ES2257794T3 (ko)
ID (1) ID23176A (ko)
IL (1) IL131615A0 (ko)
NO (1) NO994630L (ko)
NZ (1) NZ337291A (ko)
PL (1) PL335802A1 (ko)
TR (1) TR199902335T2 (ko)
TW (1) TW513307B (ko)
WO (1) WO1998042358A1 (ko)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69930419T2 (de) * 1998-11-13 2006-09-07 Eli Lilly And Co., Indianapolis Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
DE60144366D1 (de) * 2000-02-04 2011-05-19 Scripps Research Inst Neuroprotektive, antithrombotische und anti-entzündliche anwendungen von aktiviertem protein c
ES2504365T3 (es) * 2002-12-05 2014-10-08 Zz Biotech L.L.C. La actividad neuroprotectora de la proteína C activada es independiente de su actividad anticoagulante
CN100451033C (zh) * 2005-01-11 2009-01-14 北京诺赛基因组研究中心有限公司 抑制人体转录因子ap-1的基因及其编码多肽和用途
CN108159399B (zh) * 2017-12-29 2020-07-24 华中科技大学同济医学院附属同济医院 一种凝血蛋白酶aPC在防治糖尿病心肌病药物中的应用
US11217526B2 (en) 2019-02-28 2022-01-04 Taiwan Semiconductor Manufacturing Co., Ltd. Semiconductor device with source resistor and manufacturing method thereof

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
US5254532A (en) * 1989-06-26 1993-10-19 Immuno Aktiengesellschaft Fur Chemisch-Medizinische Produkte Preparation for treating and preventing thromboses and thromboembolic complications, use of such a preparation and a method of producing the same
JP2886061B2 (ja) * 1993-10-29 1999-04-26 財団法人化学及血清療法研究所 プロテインｃもしくは活性化プロテインｃの安定化方法及び安定化組成物

Also Published As

Publication number Publication date
CN1168492C (zh) 2004-09-29
ES2257794T3 (es) 2006-08-01
EP0872245B1 (en) 2006-03-08
JP2001518933A (ja) 2001-10-16
NZ337291A (en) 2001-05-25
KR20010005626A (ko) 2001-01-15
ATE319472T1 (de) 2006-03-15
PL335802A1 (en) 2000-05-22
EA199900862A1 (ru) 2000-04-24
DE69833727D1 (de) 2006-05-04
EP0872245A1 (en) 1998-10-21
WO1998042358A1 (en) 1998-10-01
DE69833727T2 (de) 2006-08-31
BR9808063A (pt) 2000-06-06
TR199902335T2 (xx) 2000-01-21
NO994630D0 (no) 1999-09-23
CN1252726A (zh) 2000-05-10
TW513307B (en) 2002-12-11
AU733756B2 (en) 2001-05-24
JP4680329B2 (ja) 2011-05-11
ID23176A (id) 2000-03-23
CA2284279A1 (en) 1998-10-01
AU6474198A (en) 1998-10-20
IL131615A0 (en) 2001-01-28

Similar Documents

Publication Publication Date Title
PT913156E (pt) Utilizacao de proteina c activada para tratar estados hipercoagulaveis associados com sepsia
HUP9700603A3 (en) Pharmaceutical preparation for the treatment of blood coagulation disorders
DE69736441D1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
HUP0000558A3 (en) Use of active d vitamin analogues for producing pharmaceutical composition for the treatment of prostatic diseases
HUP0003381A3 (en) Use of topiramate or derivatives thereof for the manufacture of a medicament for the treatment of manic-depressive bipolar disorders
NO963568D0 (no) Farmasöytisk preparat for behandling av blodkoagulasjonssykdommer, fremgangsmåter for fremstilling av dette og dets anvendelse
ATE184792T1 (de) 2-bromomelatonin zur behandlung von schlafstörungen
NO951761D0 (no) Stabilt preparat for behandling av blodkoagulasjonssykdommer
EP1029540A3 (en) Use of droloxifene for the treatment of cardiovascular diseases
ATE99932T1 (de) Verwendung von pyrrolicloncarbonsaeurealkylestern zur herstellung eines arzneimittels zur behandlung von ichtyosis.
NO973243D0 (no) Anvendelse av 3,4-difenylkromaner til fremstilling av et farmasöytisk preparat for behandling eller profylakse av gynekologiske sykdommer
DK0501705T3 (da) Anvendelse af tomoxetin til behandling af sygdomme i de nedre urinveje
HUP9904317A3 (en) Use of 1-hydroxy-2-pyridones for producing pharmaceutical compositions suitable for the treatment of skin diseases
IS1910B (is) Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
NO994630D0 (no) Metoder for behandling av vaskulaere sykdommer
NO973081D0 (no) Fremgangmåte for behandling av kroniske progressive vaskulære sykdommer
DE69739190D1 (de) Arzneimittel zur behandlung von oculären kreislauferkrankungen
DK417889D0 (da) Anvendelse af 2-azabicyklo(2.2.2.)-carboxylsyrederivater til fremstilling af medicinske produkter til behandling af vaskulaere sygdomme
ZA921101B (en) Use of tetra: Hydro-thieno-pyrido-indole derivatives for the prepartion of a medicine for the treatment of skin disorders.
GB9010389D0 (en) Pharmaceutical formulations for the treatment of peripheral vascular diseases
AU3940597A (en) Prophylaxis and therapy of the consequences of a lack of cerebral blood circulation and of neurodegenerative diseases
ATE336282T1 (de) Katheter zur behandlung von prostaterkrankungen
IT8919216A0 (it) Dispositivo per la cura chirurgica dell'astigmatismo.
EP0656208A3 (de) Verwendung von synthetischen Huminaten zur Herstellung eines Arzneimittels zur Behandlung von Schleimhauterkrankungen.
ZA925983B (en) Pharmaceutical compositions for the treatment of skin disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application